Libtayo (cemiplimab-rwlc) / Regeneron, Medison, GENESIS Pharma - LARVOL DELTA

Treatment of patients with locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) with cemiplimab as first-line systemic therapy in Slovenia. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • Non-melanoma Skin Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Evaluating the safety and effectiveness of cemiplimab in combination with platinum-doublet chemotherapy by demographic characteristics in first-line treatment of advanced non-small cell lung cancer: An ongoing multi-database real world evidence study in US patients. (ASCO 2025) - P | "Clinical Trial Registration Number: NCT06269133 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Combination therapy • HEOR • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Pilot study evaluating the addition of cemiplimab in BRAF-mutant anaplastic thyroid cancer after progression on dabrafenib and trametinib. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT04238624 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma • BRAF

Immune-related adverse events to predict outcomes in recurrent/metastatic cervical cancer treated with cemiplimab: Insights from a rescue access program in Poland. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Adverse events • Biomarker • Metastases • Cervical Cancer • Oncology • Solid Tumor

Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab in locoregionally advanced head & neck squamous cell carcinoma (HNSCC): Updated pathologic response and survival. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT04722523 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • Head and Neck Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Phase I study of induction chemoimmunotherapy (ICI) with cemiplimab in combination with cisplatin and docetaxel (TPI) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT05376553 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Combination therapy • Metastases • P1 data • Head and Neck Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Phase I trial of capecitabine with cemiplimab in patients with hormone receptor–positive metastatic breast cancer. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT05064085 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • P1 data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Trial in progress: A phase 3 randomized study of low-dose intralesional cemiplimab versus primary surgery for patients with early-stage cutaneous squamous cell carcinoma (CLEAR CSCC). (ASCO 2025) - P3 | "Clinical Trial Registration Number: NCT06585410 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • P3 data • Surgery • Non-melanoma Skin Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma. (ASCO 2025) - P2/3 | "Clinical Trial Registration Number: NCT06190951 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • P2 data • Melanoma • Oncology • Solid Tumor

A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT06171750 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Combination therapy • P1 data • Non-melanoma Skin Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Neoadjuvant cemiplimab in cutaneous basal cell carcinoma of the head and neck. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05929664 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Basal Cell Carcinoma • Head and Neck Cancer • Non-melanoma Skin Cancer • Oncology

CemiplimAb-rwlc survivorship and epidemiology (CASE): Interim results from a prospective study of the safety and effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting. (ASCO 2025) - P=N/A | "Clinical Trial Registration Number: NCT03836105 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • Real-world • Real-world evidence • Non-melanoma Skin Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

CheMo4METPANC: Combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreatic adenocarcinoma—Updated clinical and translational findings. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT04543071 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Checkpoint block • Checkpoint inhibition • Clinical • Metastases • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer

A phase 2 study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus cemiplimab plus placebo in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with positive PD-L1 expression. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT06769698 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • IO biomarker • Metastases • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT06385262 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC). (ASCO 2025) - P3 | "Clinical Trial Registration Number: NCT03969004 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • P3 data • Non-melanoma Skin Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Patient-reported outcomes (PROs) in the C-POST trial of adjuvant cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC). (ASCO 2025) - P3 | "Clinical Trial Registration Number: NCT03969004 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Patient reported outcomes • Non-melanoma Skin Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC). (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT06465329 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase 2 study of telomere-targeting agent THIO sequenced with cemiplimab in third-line immune checkpoint inhibitor–resistant advanced NSCLC: Evaluation of overall survival (OS). (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05208944 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Checkpoint inhibition • Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase 2 peri-operative study of fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy in resectable early-stage non-small cell lung cancer (NSCLC). (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT06161441 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A phase 1b study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC. (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT06088771 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase 2 expansions of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2) ± cemiplimab in patients with advanced solid tumors. (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT06090266 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • P2 data • Oncology • Solid Tumor

Safety and efficacy of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), ± cemiplimab in patients with advanced solid tumors from a phase 1 study. (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT06090266 The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Clinical • Metastases • P1 data • Oncology • Solid Tumor

Feasibility of Immune checkpoint inhibitors in Immunosuppressed Head & Neck Cutaneous Squamous Cell Carcinoma Patients (COSM 2025) - "Search terms included: immunotherapy, cemiplimab, pembrolizumab, PD-1, PD-L1, cutaneous squamous cell carcinoma, immunosuppression, transplant. While ICI is contraindicated in immunosuppressed HN cSCC patients, this state of the art review identified 22 HN cSCC patients (17 SOT) treated. The ORR of 63.6% is reported, comparable efficacy in immunocompetent individuals. Care must be taken in this population for risk of immune related adverse events, and in SOT, the risk of organ transplant rejection was reported to be 17.7%."

Checkpoint inhibition • Clinical • Human Immunodeficiency Virus • Immunology • Infectious Disease • Myelofibrosis • Non-melanoma Skin Cancer • Oncology • Solid Organ Transplantation • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Transplant Rejection • PD-1 • PD-L1

Association of socioeconomic factors and immunotherapy use in head and neck cancer (COSM 2025) - "Patients receiving immunotherapy were identified as patients receiving pembrolizumab, nivolumab, ipilimumab, cemiplimab, toripalimab-tpzi, and avelumab. Higher immunotherapy receipt in stage IV HNSCC is associated with a lower social vulnerability index, particularly based on household characteristics. Males and the northeast region were also associated with higher immunotherapy usage. While minority races were associated with higher usage, studies should further understand the reasons for these differences in immunotherapy usage."

Head and Neck Cancer • Laryngeal Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck